We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Levels of Thymidine Kinase Predict Disease Progression and Overall Survival of Metastatic Breast Cancer Patients

By LabMedica International staff writers
Posted on 25 Sep 2021
Blood serum levels of the enzyme thymidine kinase 1 (TK1) have been found to predict disease progression and overall survival of patients with metastatic hormone receptor-positive breast cancer (MBC).

Previous studies have found that elevated blood serum levels of TK1 were associated with the presence of many types of malignancy and that TK1 levels were elevated in serum even before the appearance of clinical symptoms.

Based on these findings, investigators at the University of Michigan (Ann Arbor, USA) and their colleagues at other institutions assessed the prognostic effect of TK1 in patients with hormone receptor-positive MBC treated in a prospective randomized trial of single drug treatment (anastrozole [A]) compared to dual drug treatment (anastrolzole plus fulvestrant [A+F]). More...


For this study, the investigators assessed TK1 levels in 1,726 sera from 432 patients (base line, before the start of their treatment, and at four time points during treatment) using the Biovica International (Uppsala, Sweden) DiviTum assay.

The DiviTum assay determines the enzymatic activity of TK in human serum samples. During the assay procedure, thymidine is replaced by its synthetic analog bromodeoxyuridine (BrdU), which becomes phosphorylated and then incorporated into a synthetic DNA strand fixated in each well of a 96-well ELISA immunosorbent titer-plate. The extent of BrdU incorporation depends on the activity of TK present in the serum sample; the more TK activity in the sample, the more BrdU is incorporated into synthetic DNA strands in the titer-plate well. The synthetic BrdU is then detected with anti-BrdU specific antibodies using the ELISA assay technique. The DiviTum technology amplifies the signal, enabling the assay to measure thymidine kinase activity with high sensitivity.

Results revealed that patients with high TK1 levels, either before treatment or at any time during treatment, tended to have a significantly shorter progression-free survival time (PFS). Those with high levels at the start of treatment, or baseline, had a median PFS of 11.2 months compared to 17.3 months for patients with low levels at baseline. The high-TK1 patients also survived for a shorter period of time. On average, those patients with high levels of the biomarker had median overall survival times of 30 months compared to 58 months for those with low levels.

Patients with low TK1 levels responded well to the single drug anastrozole. This finding suggested that measurement of pre-treatment TK1 levels could potentially be used to determine whether a patient should start treatment with two-drug endocrine therapy (high TK1) or a single-drug endocrine therapy (low TK1).

Contributing author Dr. Daniel Hayes, professor of internal medicine at the University of Michigan, said, “These results should serve as the basis for future clinical studies to distinguish patients with estrogen receptor metastatic breast cancer who might be best treated with endocrine therapy alone versus those who should receive endocrine therapy plus an ancillary treatment, such as CDK4/6, mTOR, or PIK3CA inhibitors. Each of these has been shown to complement endocrine therapy, but each is associated with additional side effects and costs.”

The TK1 study was published in the September 14, 2021, online edition of the journal Clinical Cancer Research.

Related Links:

University of Michigan
Biovica International


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
Laboratory Software
ArtelWare
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.